New Treatments for Menstrual Cramps on the Horizon

According to a Frontiers in Endocrinology research released in March 2021, 46% of women reported a change in their menstrual cycle, with 30% of new dysmenorrhea instances since the epidemic began. As a result, COVID-19 had a considerable impact on the dysmenorrhea treatment industry. Even after the pandemic, the market is likely to grow during the projection period due to an increase in dysmenorrhea instances and increased research and development. Dysmenorrhea is a type of menstrual cramps that affects women. The increasing frequency of dysmenorrhea among adolescent girls and rising cases of menstrual cramps due to genetic abnormalities are the primary factors driving market growth.

Access Full Report @ https://www.databridgemarketresearch.com/pt/reports/global-menstrual-cramps-treatment-market

Data Bridge Market Research analyses that the Menstrual Cramps Treatment Market was valued at USD 4,331.45 million in 2021 and is expected to reach USD 8,197.11 million by 2029, registering a CAGR of 8.30% during the forecast period of 2022 to 2029. The increased prevalence of dysmenorrhea, rising awareness and concern about dysmenorrhea among women in developed nations, and firms' engagement in producing innovative treatments all contribute to the market's growth.           

Changing lifestyle of people is expected to drive the market's growth rate

People's changing lifestyles are expected to have an impact on market dynamics throughout the projected period of 2022-2029. Changing lifestyles, along with bad eating habits, have a significant impact on the human body. As a result, the prevalence of dysmenorrhea/menstrual cramps among women has increased. Environmental changes are also thought to increase the likelihood of menstruation cramps. Furthermore, a growing number of government measures to raise awareness and increase the ageing population would result in the menstrual cramps therapy market expanding. Along with this, rising disposable income and urbanization will boost the market's growth rate.

Report Scope and Market Segmentation

Segment Analysis:

Global menstrual cramp treatment market is categorized into six notable segments which are based on type, treatment type, mode of prescription, route of administration, end user and distribution channel.

• On the basis of type, global menstrual cramp treatment market is segmented into primary dysmenorrhea and secondary dysmenorrhea. Primary dysmenorrhea segment is dominating the menstrual cramp treatment market with the market share of 57.45% as large number of patient pool suffering from primary dysmenorrhea as compared to the secondary dysmenorrhea.
• On the basis of treatment type, global menstrual cramp treatment market is segmented into medication, therapy, surgery and others. Medication segment is dominating the menstrual cramp treatment market with the market share of 46.02% as nonsteroidal anti-inflammatory drugs and combined oral contraceptives represent first-line therapy for dysmenorrhea pain.
• On the basis of mode of prescription, global menstrual cramp treatment market is segmented into prescription and over the counter. Over the counter segment is dominating the menstrual cramp treatment market with a market share of 55.23% due to most of the drugs being available generic and supplying pharmaceutical products without any hindrance and raising awareness among the masses by the virtues of advertising.
• On the basis of route of administration, global menstrual cramp treatment market is segmented into oral, parenteral, implants and others. Oral segment is dominating the menstrual cramp treatment market with a market share of 47.72% because oral segment is considered the first line of treatment. Furthermore, the growing demand for various oral drug administrations serves as another driving factor.
• On the basis of end user, global menstrual cramp treatment market is segmented into hospitals, ambulatory surgical centers, specialty centers, home healthcare and others. Hospitals segment is dominating the menstrual cramp treatment market with the market share of 44.14% because most patients are experiencing menopausal symptoms so they would be seen in the hospital to get proper diagnosis and treatment.

The hospitals segment will dominate the end user segment of the menstrual cramp treatment market

The hospitals segment will emerge as the dominating segment end user segment. This is because of the growing number of hospitals in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.

• On the basis of distribution channel, global menstrual cramp treatment market is segmented into direct tender, retail sales, pharmacies and others. Pharmacies segment is dominating the menstrual cramp treatment market with the market share of 42.27% as variety of drugs is used in hospital pharmacies to treat menopausal disorders.

The pharmacies segment will dominate the distribution channel segment of the menstrual cramp treatment market

The pharmacies segment will emerge as the dominating segment under distribution channel. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.

Major Players

Data Bridge Market Research recognizes the following companies as the major market players: Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Merck & Co., Inc. (U.S.),  F. Hoffmann-La Roche Ltd. (Switzerland), Baxter (U.S.), Bayer AG (Germany), Eli Lilly and Company (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Allergan (Ireland), AbbVie Inc. (U.S.), Abbott (U.S.), Bausch Health Companies Inc. (Canada).

Market Development

• In 2022, Pfizer announced in August that the FDA has approved relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg (MYFEMBREE) for the treatment of moderate to severe pain associated with endometriosis in premenopausal women for up to 24 months.
• In 2020, Nua announced the release of Cramp Comfort, a first-of-its-kind period pain relief solution, in December. Nua, a women's health startup, has released a revolutionary self-heating patch that can deliver up to 8 hours of heat to alleviate period pain. Cramp Comfort is made entirely of natural ingredients and was created after considerable research and a full grasp of consumer expectations. The price of a pack of three heat patches is INR 299.

Regional Analysis

Geographically, the countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

As per Data Bridge Market Research analysis:

North America is the dominant region in the menstrual cramp treatment market during the forecast period 2022 to 2029

In terms of market share and revenue, North America dominates the menstrual cramps treatment market and will maintain its dominance throughout the forecast period. This is because technological innovation and increased healthcare expenditure will drive the market's growth rate in this area even faster. Furthermore, the presence of significant key competitors and rising pharmaceutical usage will drive the market's growth rate in this area even faster.

Asia-Pacific is estimated to be the fastest growing region in the menstrual cramp treatment market in the forecast period 2022 to 2029

Given an increase in the prevalence of dysmenorrhea and menstrual health illnesses for treatment in this region, Asia-Pacific is predicted to be the fastest-growing region during the forecast period of 2022-2029. Furthermore, the expansion of healthcare infrastructure and rising government efforts would accelerate the market's growth rate in this area.

For more detailed information about the menstrual cramp treatment market report, click here – https://www.databridgemarketresearch.com/pt/reports/global-menstrual-cramps-treatment-market